Why It Matters
Dendreon Pharmaceuticals LLC is lobbying to secure inclusion of its prostate cancer immunotherapy in the Department of Veterans Affairs’ clinical treatment guidelines—a decision that determines which treatments veterans can access. Dendreon’s advocacy occurs as the VA is actively building its Precision Oncology Centers of Excellence and congressional momentum on veterans’ cancer care remains high.
By the Numbers
Dendreon spent $59,650 on in-house lobbying in the fourth quarter of 2025 through sole lobbyist Andrew Saelens. The company has maintained a continuous lobbying presence since 2010, with 72 total filings and roughly $4.46 million in expenditures. Saelens has been Dendreon’s exclusive in-house lobbyist since September 2020, filing 27 disclosures totaling approximately $2.69 million. Before joining Dendreon, he represented ZERO – the End of Prostate Cancer from 2016 to 2019. Current external partner McManus Group has worked with the company since 2019.
The Agenda
Dendreon manufactures PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for advanced prostate cancer. Its lobbying centers on the VA National Oncology Program’s Prostate Cancer Oncology Clinical Pathway, with historical focus on Medicare Part B access and veterans’ healthcare, including the Veterans Prostate Cancer Treatment and Research Act (H.R. 6092). The VA has established 21 Precision Oncology Centers of Excellence for prostate cancer—the infrastructure Dendreon is addressing through its advocacy.
Broader Context
Prostate cancer is the number one cancer diagnosis among veterans. Congress designated September 2025 as National Prostate Cancer Awareness Month, and the bipartisan PSA Screening for HIM Act is advancing to eliminate cost-sharing for high-risk screenings. The Inflation Reduction Act now includes Part B drugs in price negotiation for the first time, raising the stakes for immunotherapy manufacturers seeking favorable federal healthcare adoption.
Between The Lines
Congressional activity aligns squarely with Dendreon’s interests. Dendreon is explicitly listed as having lobbied on the PSA Screening for HIM Act (S.297/H.R.1300). The House Veterans’ Affairs Health Subcommittee held a March 2025 hearing on VA care access, and the Senate Veterans’ Affairs Committee reviewed 13 cancer-related bills. Sens. Cory Booker (D-NJ) and John Boozman (R-AR) are sponsoring early detection legislation addressing disparities affecting African American men.
Competitive Landscape
ZERO – The End of Prostate Cancer, represented by Cornerstone Government Affairs, filed a report for the fourth quarter of 2025 showing consistent focus on VA research funding, screening, and treatment. ZERO’s patient advocacy push for broader access, complements Dendreon’s efforts as a manufacturer seeking favorable clinical pathway inclusion.
The Bottom Line
Dendreon’s advocacy for PROVENGE®’s commercial viability within federal healthcare systems occurs as prostate cancer legislation advances and the VA expands precision oncology infrastructure. Despite this favorable congressional environment, Dendreon faces a narrowing window for clinical pathway inclusion, as the Inflation Reduction Act’s drug pricing provisions affecting Part B medications begins this year.
Access the Legis1 platform for comprehensive political news, data, and insights.